Trial Profile
A Phase 3, Placebo-Controlled, Randomized, Double-blind, Parallel-arm Trial to Assess the Safety and Efficacy of MAT9001 in Subjects With Severe Hypertriglyceridemia: The AMPLIFY Trial
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 20 Sep 2021
Price :
$35
*
At a glance
- Drugs Ethyl eicosapentaenoic acid (Primary)
- Indications Hypertriglyceridaemia
- Focus Registrational; Therapeutic Use
- Acronyms AMPLIFY
- Sponsors Matinas BioPharma
- 09 Sep 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 04 Jan 2021 According to Matinas BioPharma media release, the company expect to initiate this study in the second half of 2021.
- 15 Sep 2020 According to Matinas BioPharma media release, the company is evaluating several ways to both meet these requirements and to potentially provide additional data differentiating MAT9001 from other prescription omega-3 drugs.